Follow RSS for latest reports on this topicLIV-1-Positive Metastatic Breast Cancer - Market Research and Reports

Antibody-drug conjugates (ADCs) utilize the targeting ability of antibodies to deliver cytotoxic agents directly to cancer cells. Seattle Genetics is developing SGn‑lIV1a, an ADC consisting of an anti-LIV-1 (SLC39A6) monoclonal antibody linked to the synthetic cytotoxic agent monomethyl auristatin E, for the potential treatment of metastatic breast cancer.

Breast cancer is the second most common cancer in women worldwide, accounting for 16 percent of all female cancer, and is estimated to cause 500,000 deaths per year. The LIV-1 protein has been demonstrated by Seattle to be expressed in 92 percent of breast tumors analyzed, with limited expression in normal tissues.

The company initiated a phase I trial of SGNLIV1A in the U.S. in October 2013 to assess safety and antitumor activity in up to 70 LIV-1-positive metastatic breast cancer patients. The targeted approach is expected to enhance anticancer activity whilst reducing the toxic side effects of traditional chemotherapy. 

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found over 40 reports that matched your search.

Next 40 Matches >

Refine your search, and find more matches, using the form above.

Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-01-2018]

T cell is a type of white blood cell, and plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient’s body to reduce toxicity levels and restrict antigen escape (inability of immune system to respon...Read More >>>

Published:
2018-01-01

Published by: Allied Market Research

Prices Starting From:
$3840

Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022 [Report Updated: 01-08-2017]

“Global companion diagnostics market projected to grow at CAGR of 20.1%”The global companion diagnostics market is projected to reach USD 6.51 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, a...Read More >>>

Published:
2017-08-01

Published by: MarketsandMarkets

Prices Starting From:
$5650

Oncology Drugs Market Global Report 2017 Including: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicula [Report Updated: 17-07-2017]

Oncology Drugs market covers drugs that are used in the treatment of a wide range of cancer, sarcoma, and tumor. Some of the bestselling oncology drugs in 2016 include Avastin, Herceptin, Revlimid, MabThera/Rituxan, Gleevac/Glivec, Alimta, Zytiga, Tasigna, Sandostatin, and Afinitor.


The global oncology drugs market was estimated to be around 8 billion as of 2016. The oncology drugs market market made up around 11% Read More >>>

Published:
2017-07-17

Published by: The Business Research Company

Prices Starting From:
$4000

Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 18-05-2017]

CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS1.3. KEY MARKET SEGMENT1.4. RESEARCH METHODOLOGY1.4.1. Secondary research1.4.2. Primary research1.5. ANALYST TOOLS AND MODELSCHAPTER 2 EXECUTIVE SUMMARY2.1. KEY FINDINGS OF THE STUDY2.2. CXO PERSPECTIVECHAPTER 3 MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top investment pockets3.2.2. Top winning strategies3.3....Read More >>>

Published:
2017-05-18

Published by: Allied Market Research

Prices Starting From:
$5370

Breast Pumps Market by Technology (Battery Powered Breast Pumps, Manual Breast Pumps and Electric Breast Pumps), Product Type (Closed System Breast Pumps and Open System Breast Pumps) and Application (Personal Use Pumps and Hospital/Healthcare Grade Pumps) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022 [Report Updated: 13-12-2016]

Breast pumps are medical devices used for extracting milk from the breast of lactating mother. These devices are used mainly by working women to continue breastfeeding while they are at work. In some cases, physicians also recommend breast pumps to stimulate milk supply when the baby is unable to latch-on and suckle. Breast pumps have emerged as a preferable choice for the working women. The marke...Read More >>>

Published:
2016-12-13

Published by: Allied Market Research

Prices Starting From:
$5370

Breast Imaging Technologies Market by Product [Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis Positron Emission Tomography/Computed Tomography (PET/CT), Molecular Breast Imaging/Breast-Specific Gamma Imaging (MBI/BSGI), Cone Beam Computed Tomography (CBCT), Positron Emission Mammography (PEM)); and Non-Ionizing Breast Imagin [Report Updated: 09-12-2016]

Breast imaging technologies are used for the early detection of breast-related disorders. These technologies are mainly used to detect breast cancer at its initial stages. Various imaging modalities such as mammography, MRI, and ultrasound facilitate in the screening and staging of breast cancer by identifying characteristic masses or calcifications in the breast tissue.nnThe global breast imaging...Read More >>>

Published:
2016-12-09

Published by: Allied Market Research

Prices Starting From:
$5370

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognosti [Report Updated: 01-12-2016]

Cancer biomarkers are biomolecules that specifies the existence of cancer or cancerous cells in the body. These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer. These molecules are densely distributed in tissues, urine, serum, blood, and other body fluids. Their expression levels serve as the basis or indicat...Read More >>>

Published:
2016-12-01

Published by: Allied Market Research

Prices Starting From:
$5370

Breast Imaging Market: By Technology (Ionizing Technologies (Mammography, Digital, 3D Mammography, MBI, PET-CT, CBCT, PEM), Non-ionizing Technologies (Breast MRI, Breast Ultrasound, AWBU, Breast Thermography, Optical Imaging)) -Forecast (2016-2021) [Report Updated: 29-03-2016]

Breast imaging is a technology that is widely used to obtain a high resolution visualization of breast and related diseases. Breast cancer is the most common cancer found in women. Breast imaging techniques play a major role in early diagnosis of the disease by evaluating the advancement of the disease and deciding which treatment is suitable. This breast imaging technique enables doctors to obser...Read More >>>

Published:
2016-03-29

Published by: Industry ARC

Prices Starting From:
$5250

Published:
2016-01-04

Published by: Industry ARC

Prices Starting From:
$5250

Published:
2015-12-02

Published by: MarketsandMarkets

Prices Starting From:
$5650

Companion Diagnostics Market: By Technology (PCR, Polymerase Chain Reaction (PCR), ISH, IHC, Others) Applications (Breast Cancer, Lung Cancer, Gastric Cancer, Others) End Users (Pharmaceuticals, Laboratries, Research Institutes, Others)-Forecast(2017-2022) [Report Updated: 18-07-2015]

Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for their patients. The companion diagnostic is crucial for the safe and effective use of the drug and have been widely developed for myriad of cancer and other therapies. Each companion diagnostic test is specifically designed to be paired with a specific drug. Such tests can also save s...Read More >>>

Published:
2015-07-18

Published by: Industry ARC

Prices Starting From:
$5250

Published:
2015-06-10

Published by: MarketsandMarkets

Prices Starting From:
$5650

Additional Searches

You may also like to search separately for: LIV-1-Positive Metastatic Breast Cancer

We Stock...

{STICKYFOOTERMOBILE}